Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Uncomplicated skin and skin structure infections,Complicated skin and skin structure infections,Complicated intra-abdominal infections,Urinary tract infections,Acute pyelonephritis,Chronic bacterial prostatitis,Inhalational anthrax (post-exposure),Plague
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
400 mg intravenously once daily. Infuse over 60 minutes.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life of moxifloxacin is approximately 11-15 hours in patients with normal renal function; allows once-daily dosing.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Hepatic via glucuronide and sulfate conjugation; CYP450 system not significantly involved.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal (approximately 45-60% as unchanged drug and metabolites); biliary/fecal (approximately 20-25% as unchanged drug and metabolites); total urinary and fecal recovery >95%.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Approximately 40-50% bound to serum proteins, primarily albumin.
Low protein binding; 0–11% bound, primarily to albumin.
Volume of distribution is approximately 2.8 L/kg; indicates extensive tissue penetration, including into lungs, sinuses, skin, and soft tissues.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% (complete immediate bioavailability).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
For GFR <30 m L/min, reduce dose to 400 mg intravenously every 48 hours.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Safety and efficacy not established in pediatric patients under 18 years.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No routine dosage adjustment required based on age alone; monitor renal function and adjust as per renal impairment guidelines.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients older than 60 years, those taking corticosteroids, and those with kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with known history of myasthenia gravis.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
May prolong QT interval; avoid in patients with known QTc prolongation, uncorrected hypokalemia, or receiving class IA or III antiarrhythmics. Use with caution in patients with CNS disorders (e.g., epilepsy). Discontinue if signs of tendon pain, inflammation, or rupture occur. May cause peripheral neuropathy. Use with caution in patients with renal impairment. Avoid in patients with known hypersensitivity to fluoroquinolones.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to moxifloxacin or any fluoroquinolone; history of tendinopathy with fluoroquinolones; patients with myasthenia gravis; pregnancy (category C); nursing mothers; children <18 years; patients with known QTc prolongation or uncorrected electrolyte disturbances.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, avoid alcohol as it may increase risk of dizziness and gastrointestinal side effects. Keep well hydrated.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones are limited. First trimester exposure is not associated with major malformations; however, second and third trimester exposure may be linked to fetal bone and cartilage damage. Use during pregnancy should be reserved for infections where no alternatives exist.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Moxifloxacin is excreted into human milk at very low concentrations. The M/P ratio is approximately 0.68. The estimated infant dose is less than 1% of the maternal dose. Caution is advised due to potential for infant joint damage, but no adverse effects reported. Consider interruption of breastfeeding during therapy and for 48 hours after last dose.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy-induced physiological changes (increased volume of distribution, enhanced renal clearance) may lower moxifloxacin plasma concentrations. However, no specific dose adjustments are recommended due to lack of dedicated pharmacokinetic studies in pregnancy. Standard adult dosing (400 mg IV once daily) is used, with caution and consideration of increased clearance potential.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
AVELOX (moxifloxacin) in sodium chloride 0.8% is a fluoroquinolone antibiotic for intravenous use. Avoid rapid infusion; administer over 60 minutes to reduce risk of infusion-related reactions. Monitor for QT prolongation, especially in patients with electrolyte disturbances or on antiarrhythmics. Avoid in patients with known aortic aneurysm or history of tendinopathy. Use caution in elderly and those with renal impairment. Not recommended for patients with myasthenia gravis due to risk of exacerbation.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is given intravenously (IV) and must be infused slowly over at least 60 minutes.,You may experience side effects like nausea, diarrhea, dizziness, or headache. Report severe or persistent symptoms.,Watch for signs of tendon pain or swelling, especially in the shoulder or calf. Stop the medication and seek medical attention if this occurs.,Avoid driving or operating machinery if you experience dizziness or vision changes.,Tell your doctor if you have a history of heart rhythm problems, seizures, or low potassium/magnesium levels.,Use sunscreen and protective clothing to avoid sun sensitivity reactions while on this medication.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily. Infuse over 60 minutes.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones . AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.